Ezrin expression in circulating tumor cells is a predictor of prostate cancer metastasis

References

• Centers for Disease Control and Prevention. QuickStats: age-Adjusted Death Rates* from prostate cancer,(dagger) by Race/ Ethnicity - national vital statistics system, United States, 1999-2017. MMWR Morb Mortal Wkly Rep. 2019;68(23): 531.
   PubMed Web of Science ®Google Scholar
• Cysouw MCF, Kramer GM, Heijtel D, et al. Sensitivity of (18)F-fluorodihydrotestosterone PET-CT to count statistics and reconstruction protocol in metastatic castration-resistant prostate cancer. EJNMMI Res. 2019;9(1): 70.
   PubMedGoogle Scholar
• Fu ZT, Guo XL, Zhang SW, et al. [Statistical analysis of incidence and mortality of prostate cancer in China, 2015]. Zhonghua Zhong Liu Za Zhi. 2020;42(9): 718–722.
   PubMedGoogle Scholar
• Elsherif SB, Kuchana V, Aslam R, et al. Locally advanced prostate cancer imaging findings and implications for treatment from the surgical perspective. Abdom Radiol (NY). 2020;45(3): 865–877.
   PubMed Web of Science ®Google Scholar
• Tan YG, Poon RJ, Pang LJ, et al. Comparative study of surgical orchidectomy and medical castration in treatment efficacy, adverse effects and cost based on a large prospective metastatic prostate cancer registry. Urol Oncol. 2020;38(8): 682 e1–682 e9.
   PubMed Web of Science ®Google Scholar
• Xu N, Ke ZB, Chen YH, et al. Risk factors for pathologically confirmed lymph nodes metastasis in patients with clinical T2N0M0 stage prostate cancer. Front Oncol. 2020;10: 1547.
   PubMed Web of Science ®Google Scholar
• Taneja SS. Re: denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Urol. 2014;192(2): 421–422.
   Web of Science ®Google Scholar
• Bittner N, Merrick GS, Andreini H, et al. Prebiopsy PSA velocity not reliable predictor of prostate cancer diagnosis, Gleason score, tumor location, or cancer volume after TTMB. Urology. 2009;74(1): 171–176.
   PubMed Web of Science ®Google Scholar
• Leidinger P, Hart M, Backes C, et al. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, gleason score, or TNM status. Tumour Biol. 2016;37(8): 10177–10185.
   PubMedGoogle Scholar
• Fenton JJ, Weyrich MS, Durbin S, et al. Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the US preventive services task force. JAMA. 2018;319(18): 1914–1931.
   PubMed Web of Science ®Google Scholar
• Force USPST, Grossman DC, Curry SJ, et al. Screening for prostate cancer: US preventive services task force recommendation statement. JAMA. 2018;319(18): 1901–1913.
   PubMed Web of Science ®Google Scholar
• Liu W, Yin B, Wang X, et al. Circulating tumor cells in prostate cancer: precision diagnosis and therapy. Oncol Lett. 2017;14(2): 1223–1232.
   PubMed Web of Science ®Google Scholar
• Galletti G, Portella L, Tagawa ST, et al. Circulating tumor cells in prostate cancer diagnosis and monitoring: an appraisal of clinical potential. Mol Diagn Ther. 2014;18(4): 389–402.
   PubMed Web of Science ®Google Scholar
• Yang M, Zhang X, Guo L, et al. Research progress for the clinical application of circulating tumor cells in prostate cancer diagnosis and treatment. Biomed Res Int. 2021;2021: 6230826.
   PubMed Web of Science ®Google Scholar
• Faugeroux V, Lefebvre C, Pailler E, et al. An accessible and unique insight into metastasis mutational content through whole-exome sequencing of circulating tumor cells in metastatic prostate cancer. Eur Urol Oncol. 2020;3(4): 498–508.
   PubMed Web of Science ®Google Scholar
• Saygideger-Kont Y, Minas TZ, Jones H, et al. Ezrin enhances EGFR signaling and modulates erlotinib sensitivity in non-small cell lung cancer cells. Neoplasia. 2016;18(2): 111–120.
   PubMed Web of Science ®Google Scholar
• Xiong C, Wang G, Bai D. A novel prognostic models for identifying the risk of hepatocellular carcinoma based on epithelial-mesenchymal transition-associated genes. Bioengineered. 2020;11(1): 1034–1046.
   PubMed Web of Science ®Google Scholar
• Hoskin V, Szeto A, Ghaffari A, et al. Ezrin regulates focal adhesion and invadopodia dynamics by altering calpain activity to promote breast cancer cell invasion. Mol Biol Cell. 2015;26(19): 3464–3479.
   PubMed Web of Science ®Google Scholar
• Elzagheid A, Korkeila E, Bendardaf R, et al. Intense cytoplasmic ezrin immunoreactivity predicts poor survival in colorectal cancer. Hum Pathol. 2008;39(12): 1737–1743.
   PubMed Web of Science ®Google Scholar
• Chen QY, Xu W, Jiao DM, et al. Silence of ezrin modifies migration and actin cytoskeleton rearrangements and enhances chemosensitivity of lung cancer cells in vitro. Mol Cell Biochem. 2013;377(1–2): 207–218.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang L, Zhang G, et al. Osteosarcoma metastasis: prospective role of ezrin. Tumour Biol. 2014;35(6): 5055–5059.
   PubMedGoogle Scholar
• Zhang X, Li G, Guo Y, et al. Regulation of ezrin tension by S-nitrosylation mediates non-small cell lung cancer invasion and metastasis. Theranostics. 2019;9(9): 2555–2571.
   PubMed Web of Science ®Google Scholar
• Ghaffari A, Hoskin V, Turashvili G, et al. Intravital imaging reveals systemic ezrin inhibition impedes cancer cell migration and lymph node metastasis in breast cancer. Breast Cancer Res. 2019;21(1): 12.
   PubMedGoogle Scholar
• Chen Z, Hou R, Gao S, et al. Baicalein inhibits proliferation activity of human colorectal cancer cells HCT116 through downregulation of Ezrin. Cell Physiol Biochem. 2018;49(5): 2035–2046.
   PubMedGoogle Scholar
• Meseure D, Drak Alsibai K, Nicolas A. Pivotal role of pervasive neoplastic and stromal cells reprogramming in circulating tumor cells dissemination and metastatic colonization. Cancer Microenviron. 2014;7(3): 95–115.
   PubMedGoogle Scholar
• Yang L, Lv Z, Xia W, et al. The effect of aspirin on circulating tumor cells in metastatic colorectal and breast cancer patients: a phase II trial study. Clin Transl Oncol. 2018;20(7): 912–921.
   PubMed Web of Science ®Google Scholar
• Iwata H, Masuda N, Yamamoto D, et al. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat. 2017;162(3): 501–510.
   PubMed Web of Science ®Google Scholar
• Papanikolaou S, Vourda A, Syggelos S, et al. Cell plasticity and prostate cancer: the role of epithelial-mesenchymal transition in tumor progression, invasion, metastasis and cancer therapy resistance. Cancers (Basel). 2021;13(11): 11.
   Web of Science ®Google Scholar
• Zhang YP, Cheng YB, Li S, et al. An epithelial-mesenchymal transition-related long non-coding RNA signature to predict overall survival and immune microenvironment in kidney renal clear cell carcinoma. Bioengineered. 2021;12(1): 555–564.
   PubMed Web of Science ®Google Scholar